Observational studyEndocrine2025
Glycemia risk index in pediatric type 1 diabetes: A retrospective observational study of a novel metric for assessing glycemic control and variability.
Observational study in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContinuous glucose monitoring (CGM) provides detailed insights into glycemic patterns in type 1 diabetes (T1D), yet clinical interpretation remains complex because of multiple interdependent metrics. The Glycemia Risk Index (GRI) has been proposed as a novel composite metric integrating hyperglycemia and hypoglycemia risk. However, limited data exist on its application in pediatric T1D. This study evaluates the GRI’s correlation with standard CGM metrics and HbA1c in children and adolescents with T1D.
methodsThis retrospective observational study analyzed 307 ambulatory glucose profile (AGP) reports from pediatric patients (≤ 18 years) with T1D using CGM. Key glycemic metrics, including Time in Range (TIR), Time Below Range (TBR), Time Above Range (TAR), Glycemic Management Indicator (GMI), and Coefficient of Variation (CV), were extracted. GRI was calculated using a standard formula and compared across different TIR and HbA1c categories. Correlations between GRI and CGM metrics were assessed using Spearman’s rank correlation, with statistical significance set at p < 0.05.
resultsAmong 173 participants (mean age 10.1 ± 4.0 years, 50.5% male), median diabetes duration was 23.0 months (IQR: 14.5–41.5). Median TIR 57.0% (42.0–69.0%) with median GRI 57.6 (IQR: 35.2–78.0). GRI demonstrated a strong negative correlation with TIR (ρ = -0.969, p < 0.001), strong positive correlations with TAR (ρ = 0.919, p < 0.001) and CV (ρ = 0.879, p < 0.001), and a moderate positive correlation with HbA1c (ρ = 0.482).
conclusionGRI correlates strongly with CGM-derived glycemic variability and hyperglycemia exposure in pediatric T1D. Its ability to integrate both hypo- and hyperglycemia into a single metric suggests it’s a useful adjunct to HbA1c and TIR in clinical decision-making.
Indexed as
Identifiers
41460551What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.